Mykofenolsyra Accord (Mycophenolic Acid)

Mykofenolsyra Accord, an antimetabolite immunosuppressant, is indicated for several immune‑mediated conditions.

• Organ transplant rejection: helps prevent acute and chronic rejection episodes in kidney, heart and liver transplants.
• Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus.
• Severe autoimmune disorders: may be employed as part of combination therapy for conditions such as systemic sclerosis or vasculitis where strong immunosuppression is required.

• Mycophenolic Acid selectively inhibits inosine monophosphate dehydrogenase (IMPDH), the key enzyme for de novo synthesis of guanosine nucleotides. By limiting guanosine availability, the drug suppresses proliferation of T and B lymphocytes, which rely heavily on this pathway, while sparing most other cell types. This targeted inhibition reduces the immune response that drives graft rejection and autoimmune tissue damage.

Mykofenolsyra Accord may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools that may lead to dehydration.
• Headache: transient cranial discomfort.
• Infections: increased susceptibility to bacterial, viral or fungal infections.

Serious or Rare Side Effects

• Leukopenia: significant reduction in white blood cells.
• Anemia: decreased red blood cell count causing fatigue.
• Malignancy risk: potential increased incidence of lymphoproliferative disorders.

Before initiating Mykofenolsyra Accord, clinicians should consider several precautionary measures to ensure safe use.

• Monitor blood counts: perform regular complete blood count testing.
• Assess renal function: evaluate serum creatinine and glomerular filtration rate.
• Avoid live vaccines: live attenuated vaccines may cause infection.
• Use effective contraception: prevent pregnancy due to potential teratogenicity.
• Adjust dose in hepatic impairment: consider reduced dosing in patients with liver dysfunction.
• Store at room temperature below 25°C: keep in the original packaging, protect from moisture.

Mykofenolsyra Accord can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., azole antifungals): increase mycophenolic acid exposure.
• Live vaccines: heightened risk of infection.
• Concurrent bone‑marrow suppressants (e.g., azathioprine): additive hematologic toxicity.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may reduce oral absorption.
• NSAIDs: increase risk of gastrointestinal bleeding.
• ACE inhibitors or ARBs: may worsen renal function when combined.